Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

BioTime's Hextend enters European clinical trials; licensed to Abbott

July 28, 1997

Forbes Medi-Tech submits patent, reports on clinical trials

July 28, 1997

New approaches to the pharmacological treatment of obesity

July 25, 1997

Infant nutrition as a way of preventing IDDM

July 25, 1997

Diabetes classification not as clear-cut as previously thought

July 25, 1997

Genetics Institute's growth factor recommended for approval by advisory committee

July 25, 1997

Selective neuropeptide Y5 receptor antagonists described by Synaptic

July 25, 1997

HRT indicated in hypertensive women

July 25, 1997

HRT inhibits ACE in postmenopausal women

July 25, 1997

More light shed on leptin and leptin receptors

July 24, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...